Quality Research
Join today!

Awakn Life Sciences Corp (OTCQB:AWKNF / NEO:AWKN) Pioneering Psychedelic Therapies to Treat AUD

Awakn Life Sciences is a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder.

Awakn Life Sciences Corp ( OTCQB:AWKNF / NEO:AWKN) Pioneering Psychedelic Therapies to Treat AUD

Market For Psychedelic therapies for addiction and Alcohol Use Disorder

In the last decade psychedelic agents have transitioned from taboo whispers to being accepted as an innovative remedy among some of the worst disorders across the globe. These include alcohol use disorder, substance abuse, and depression among many more.

The journey of acceptance isn’t complete, but it is off to a strong start. In May 2021, the first Phase-3 clinical trial was conducted utilizing MDMA in combination with psychological counseling sessions. The trial results concluded “treatment efficacy in individuals with severe PTSD, and patient safety”.

According to JAMA Psychiatry, “The market for psychedelic substances is projected to grow from $2 billion in 2020 to $10.75 billion by 2027, a growth rate that may even outpace the legal US cannabis market.”


Research and Development


  • Awakn has acquired the exclusive rights to the worlds only Phase IIa clinical trial for MDMA-assisted therapy to treat AUD led by world renowned addiction experts, Prof. David Nutt, Dr. Ben Sessa, Dr. Laurie Higbed


  • NCE development program with Evotec (NASDAQ: EVO)


  • A completed Phase IIa/b trial for Ketamine-Assisted Therapy to treat AUD.


  • In January, Awakn announced positive results from their Phase II A/B Clinical Trials, indicating that “Primary and secondary endpoints achieved, including 86% abstinence over 6 months post treatment and no serious adverse events” and impressively showing the potential in a decrease in mortality rate “Within the KARE group there was also a significant decrease in the risk of mortality, 1 in 8 patients would have died within 12 months without treatment, that number decreased to 1 in 80 following the treatment.”


  • The secondary outcomes of the study identified further encouraging results including improved liver function across several different markers, a statistically significant decrease in depression after 3 months and an increase in the ability to experience pleasure


Clinical Pipeline



Awakn is led by passionate CEO and industry expert, Anthony Tennyson, who has extensive experience in financial services, including, international strategy, commercial leadership roles with Aon plc, and 5 years with Merrill Lynch and Bank of Ireland.

Stacked scientific and research professionals spanning technology, healthcare and psychedelic areas of research.

Recent addition of special advisor Dennis Purcell who has a track record in investment banking focused on pharmaceuticals, biotechnology, and medical products. As well as an extensive resume of director roles in successful biotechnology and pharmaceutical companies. 


Clinical Expansion

  • Awakn Clinics Bristol received Care Quality Commission’s (CQC) formal approval to begin treatments.
  • Target to open 15-20 clinics by the end of 2024.
  • Up to CA$5m projected annual revenue per clinic or ∼$3.8m USD.
  • Potential licensing opportunities to expand operations in the United States and Canada.

Where does Awakn stand among competitors?

Financial & Technical Takeaways

  • Cash on hand: $2.8m
  • Convertible Debt: Nil
  • Current outstanding shares: 26.9m
  • Fully diluted shares: 31m
  • Insider ownership: 30%


  • 52-week share high- 2.71
  • 52-week share low- .69
  • RSI: 26.36
  • 18.9m Market Cap

Data as of 6/13/22

Share structure via OTCMarkets.com *Updated 6/10/22*

Analyst report from investment banking firm Stifel GMP set a price target of $8.00



Learn More
Investor & Media Enquiries:

CEO Awakn Life Sciences
Anthony Tennyson


Editorial Contact:

CEO Stockify Media
Ryan Shea



Sign up for weekly alerts!


IMPORTANT NOTICE: The owner and contributors are NOT registered as Investment Advisers in any form at all. Readers should verify all claims and content from Stockify Media or affiliates. We encourage proper due diligence on any security mentioned. Likewise, note that by presenting a solicitation for a page on our site, or by pursuing any Stockify Media content you are unequivocally consenting to have read, comprehended, and consented to the entirety of the terms set out by this disclaimer. This disclaimer is provided because we are in the business of publishing advertisements and disseminating information on penny stocks. Therefore, certain communication disclosures must be made to viewers. The companies are commonly referred to as “penny stocks”. These “penny stock” securities are known to have high risk and speculative nature on the market. Stockify Media provides all buy, sell, or holding period disclosures on any profiled issuer. All our compensated disclosures can be viewed under the “Compensation Disclosure” heading at the bottom of this disclaimer. Stockify Media engages in posting and re-posting our sponsored clients public material.  Stockify Media does not hold any position in the mentioned companies above. We have been compensated for this profile. Stockify Media, managers, and site contributors are not registered investment advisors in any form. Stockify Media is not responsible for maintaining the accuracy, integrity, and relevancy of third-party source data used in profiles. None of our information provided is a solicitation to buy or sell any security profiled by Stockify Media, LLC/Stockify Media. Our content is strictly for informational purposes only. This information is not intended and should not be used to make any investment decisions. We advise viewers to consult with a registered investment advisor prior to making any investment decisions. You are fully aware that you will lose your entire investment in any stocks mentioned. Our full disclaimer can be viewed here.